Watch Dr. Sena’s interview about a metastatic prostate cancer case report in which PICTograph was used to model the outgrowth of a subclone with acquired resistance to targeted therapies. Read the paper from NPJ Precision Oncology here: Intratumoral heterogeneity drives acquired therapy resistance in a patient with metastatic prostate cancer.